03 Profile
Vital Signsby Bridgehead
Hansard to 9 November 2026 · 31,243 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Academic · Respiratory (asthma/COPD)
Gabor Kovacs: no photograph is held, so the academic plate is shown instead.
Academic
Gabor Kovacs
MD, Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria, lead author of the 2026 guidelines
1
0
0
Sept 2026Oct 2026Nov 2026to date
1
press citation on 1 topic since 23 Sept 2026 · last quoted 23 Sept 2026
02 Quoted on · 1 of 29 topics
Gabor Kovacs: key facts
- Kind of voice
- Academic
- Role
- MD, Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria, lead author of the 2026 guidelines
- Quoted on
- Respiratory (asthma/COPD)
- Tracked press citations
- 1
- Most recently quoted
- 23 Sept 2026
04 The signal · where Gabor Kovacs sits on respiratory (asthma/copd)
Ranked 51= of 100 voices quoted in the press on respiratory (asthma/copd), level with 49 others on 1 citation.
Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.
- 1=Darush Attar-ZadehClinicianExecutive Chair, Primary Care Respiratory Society; Clinical Fellow Respiratory Pharmacist, North West London Integrated Care Board, Primary Care Respiratory Society (PCRS)7
- 1=
Dr Andy WhittamoreClinicianClinical Lead (and practising GP), Asthma + Lung UK7 - 3
Alvar Agusti, MD, PhDAcademicProfessor of Medicine; Chair, GOLD Board of Directors, University of Barcelona / Hospital Clínic de Barcelona5 - 51=Daiana StolzAcademicProfessor of respiratory medicine at the University Hospital Freiburg in Germany1
- 51=David MontaniAcademicMD, PhD, pulmonologist at the French National Referral Center for Pulmonary Hypertension at Bicêtre Hospital in Le Kremlin-Bicêtre, France1
- 51=Gabor KovacsAcademicMD, Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria, lead author of the 2026 guidelines1
Showing the leaders and the ranks around 51=, of 100 voices · See every voice on the topic →
05 On the record · press
What Gabor Kovacs has said
By outlet · linked articles
- medscape.com1
Where Gabor Kovacs has been quoted
- 01New European Guidelines Update Pulmonary Hypertension Caremedscape.com · 23 Sept 2026
Verbatim
“However, since then, major advances have expanded the therapeutic arsenal. In 2024, sotatercept, the first activin signaling pathway inhibitor of its class, was approved by the FDA and the EMA for the treatment of PAH. An update was necessary.”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
- Positive First ILD Pulmonary Rehabilitation programme for patients in the Omagh, Strabane and Fermanagh areaWestern Health & Social Care Trust
- Americans Are Open to Lung Cancer Screening, but Awareness and Education Have Not Caught UpIpsos
- Hospital trust admits mother’s death from missed pulmonary embolism was avoidable as family receives settlementLeigh Day
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.